Preliminary Q2 2026 Evotec SE Earnings Call Transcript
Key Points
- Evotec SE (EVO) reported a quarterly increase in liquidity, reaching EUR465.6 million, driven by proceeds from Gilead's acquisition of Tubulis and a convertible bond placement.
- The company has seen a 28% increase in net sales in its base discovery and preclinical development (D&PD) business for the first half of 2026 compared to the same period in 2025.
- Evotec SE (EVO) has successfully implemented the Horizon transformation, which is expected to yield EUR75 million in cost savings by the end of 2027.
- The company has strengthened its management team with key appointments, including a new Chief Commercial Officer and Chief Operating Officer, to enhance commercial engagement and operational excellence.
- Evotec SE (EVO) has a healthy and active partnership pipeline with multiple opportunities at various stages of engagement, including advanced discussions with potential big pharma partners.
- Evotec SE (EVO) reported a decrease in group revenues by approximately 19% for the first half of 2026 compared to the same period in 2025.
- The company revised its full-year 2026 guidance due to delays in strategic partnerships and lower-than-expected revenue conversion.
- Adjusted group EBITDA is expected to be negative, ranging from minus EUR70 million to minus EUR105 million for the full year 2026.
- Unfavorable foreign exchange movements have added a headwind of EUR13 million to the first half revenues.
- The timing of revenue conversion from strategic partnerships has been slower than anticipated, impacting the company's short-term financial performance.
Good morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Fakih, and I'm the Head of Global Communications and Investor Relations at Evotec.
Please allow me to introduce today's speakers. Joining me on the call are Christian Wojczewski, Chief Executive Officer of Evotec, and Claire Hinshelwood, our Chief Financial Officer. Please note that this call is being webcast live and will be archived in the events calendar on our website.
Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's views as of today, Tuesday, July 14, 2026. During this call, we will make statements and provide responses that state our intentions, beliefs, expectations, or projections regarding the future. These statements constitute forward-looking statements within the meaning of applicable securities laws. They are subject to risks and uncertainties, and actual results may differ materially from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
